Breaking News - The Fly

Open Search

OCS

Oculis

$

()

Oculis announces listing on Nasdaq Iceland Main Market

OCS

4/11/2024 - 08:58am

Oculis names Dr. Snehal Shah as President of Research & Development

OCS

4/10/2024 - 06:33am

Oculis announces 'positive' results from Phase 3 OPTIMIZE-1 trial of OCS-01

OCS

4/8/2024 - 06:34am

Oculis files $300M mixed securities shelf

OCS

4/1/2024 - 06:56am

Oculis price target lowered by $29 at Baird, here's why

OCS

3/19/2024 - 06:50am

Oculis provides update on progress of its late-stage clinical trials

OCS

2/28/2024 - 06:45am

Chardan lays out top 4 biotech picks for 2024

ALNY , RNA , LXEO

…

2/2/2024 - 08:52am

Oculis at H.C. Wainwright, here's why

OCS

12/20/2023 - 10:58am

Oculis announces first patient first visit in Phase 3 OPTIMIZE-2 trial of OCS-01

OCS

12/20/2023 - 06:33am

Oculis reports first patient visit in Phase 3 DIAMOND-1 trial of OCS-01

OCS

12/18/2023 - 06:44am

Oculis announces FPFV in Phase 2b RELIEF trial of licaminlimab

OCS

12/7/2023 - 06:35am

Chardan starts Oculis with Buy on diabetic macular edema potential

OCS

12/5/2023 - 05:58am

Oculis initiated with bullish view at Chardan

OCS

12/5/2023 - 05:36am

Oculis price target lowered to $21 from $24 at BofA

OCS

11/16/2023 - 07:25am

Oculis' OCS-01 eye drops meet primary and secondary Phase 3 endpoints in DME

OCS

10/10/2023 - 06:35am